Enzyme immunoassay for the semi-quantitative determination (screening) of total and free antibodies to infliximab in serum and plasma.
SHIKARI® Semi-Quantitative Free/Total Antibodies to Infliximab ELISA is a sandwich assay for the determination of total and free antibodies against infliximab in serum and plasma samples. During the first incubation period, the separation of infliximab specific antibody- infliximab immune complex is provided by adding dissociation buffer. After transferring dissociation mix to the plate, infliximab antibodies are separated from infliximab in patient serum/plasma samples and they are captured by the drug infliximab coated on the wall of the microtiter wells and horse radish peroxidase (HRP) conjugated probe. After washing away the unbound components from samples, the bound enzymatic activity is detected by addition of tetramethylbenzidine (TMB) chromogen substrate. Finally, the reaction is terminated with an acidic stop solution. The intensity of the reaction colour is directly proportional to the concentration of infliximab antibodies in sample.
This kit can be also used as a semi-quantitative test for free anti-drug antibodies determination without dissociation and neutralization steps.
Free and Total Anti drug Antibody monitoring gained high importance along with measuring free drug from the patient samples. In order to make these measurements simple yet more informative. We have produced SHIKARI® Q-ATI DUO to measure Free and Total anti drug antibodies to Infliximab simultaniously on the same plate. The kit is semi-quantitative and enables follow up of the patients to adjust the dose of the drug and/or frequency of administration
All SHIKARI® ELISA kits are suitable for biosimilar work.
